Symbol | Exchange | Currency |
|---|
Investing.com - Benitec Biopharma ADR reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Benitec Biopharma ADR...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Technology, Healthcare and Consumer Goods sectors led shares lower. At the close in NYSE, the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Sell | Sell | Strong Sell |
| Technical Indicators | Sell | Sell | Strong Sell | Sell | Sell |
| Summary | Neutral | Neutral | Strong Sell | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 146.92 | 147.47 | 145.56 | +0.09 | +0.06% | 53.16M | NASDAQ | |||
| 2,844.30 | 2,846.60 | 2,804.80 | +20.0 | +0.71% | 1.14M | NASDAQ | |||
| 352.96 | 354.35 | 342.37 | +7.00 | +2.02% | 18.74M | NASDAQ | |||
| 43.94 | 44.41 | 43.81 | -0.25 | -0.57% | 16.00M | NYSE | |||
| 149.59 | 151.85 | 148.00 | -9.99 | -6.26% | 26.85M | NYSE | |||
| 15.29 | 15.35 | 15.15 | -0.07 | -0.46% | 330.15K | NASDAQ | |||
| 6.62 | 6.63 | 6.57 | +0.110 | +1.69% | 1.17M | NYSE | |||
| 10.14 | 10.14 | 10.04 | -0.19 | -1.84% | 150.39K | NYSE | |||
| 33.29 | 33.47 | 33.23 | +0.15 | +0.45% | 130.33K | NYSE | |||
| 2,852.70 | 2,858.10 | 2,817.00 | +16.1 | +0.57% | 741.74K | NASDAQ | |||
| 9.35 | 9.49 | 9.00 | +0.21 | +2.30% | 93.97K | NASDAQ | |||
| 28.07 | 28.31 | 27.93 | -0.93 | -3.21% | 13.21K | NYSE | |||
| 6.32 | 6.62 | 5.63 | +0.080 | +1.28% | 44.39M | NASDAQ | |||
| 53.89 | 54.24 | 53.86 | -0.15 | -0.28% | 9.66M | NYSE | |||
| 163.04 | 163.59 | 160.82 | +1.86 | +1.15% | 9.67M | NYSE |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.